Last updated 2026-08-22
- Raised Seed round led by Arieli Group, Dec 2024
Total raised
—
Last: Undisclosed Round 2024-11
Stage
Pre-Seed
Founded
2024
Headcount
7
HQ
Nazareth, Israel
Sector
Drug Discovery
Website ↗Registrar ID: 517016606 (GRACE GENE THERAPY LTD)
About
Grace Gene Therapy is an Israeli startup focused on developing a revolutionary gene therapy treatment for Parkinson's disease. The company's unique approach involves a chemogenetic agent that selectively targets the diseased region of the brain with a precise biological neuromodulator, operating independently of the dopaminergic system. This treatment aims to fix neural network problems caused by Parkinson's disease by adjusting parts of the brain using DREADDs (Designer Receptors Exclusively Activated by Designer Drugs). The company holds granted patents in multiple regions, including the USA, EU, China, Canada, and Japan.
Funding history · 1 round · — total
1 event/round · — Total Funding
Dec 2024
Offices
Nazareth, Israel · HQ / main office
Q&A
- What is Grace Gene Therapy's primary focus?
- Grace Gene Therapy is an Israeli startup focused on developing a gene therapy treatment for Parkinson's disease, utilizing a chemogenetic agent that selectively targets diseased brain regions.
- When was Grace Gene Therapy founded?
- Grace Gene Therapy was founded in 2024.
- Where is Grace Gene Therapy headquartered?
- Grace Gene Therapy is headquartered in Nazareth, Israel.
- How many employees does Grace Gene Therapy currently have?
- Grace Gene Therapy has 7 employees, falling within the 1-10 employee bucket.
- What is the current product stage of Grace Gene Therapy?
- Grace Gene Therapy is currently in the R&D product stage.
- What is Grace Gene Therapy's primary sector?
- Grace Gene Therapy's primary sector is Health Tech & Life Sciences.
- Who are the co-founders of Grace Gene Therapy?
- The co-founders of Grace Gene Therapy are Fadi Assaf, who also serves as CEO, and Yitzhak Schiller.
- What is Grace Gene Therapy's approach to treating Parkinson's disease?
- Grace Gene Therapy's approach involves using a chemogenetic agent that selectively targets the diseased region of the brain with a precise biological neuromodulator, operating independently of the dopaminergic system, and utilizing DREADDs (Designer Receptors Exclusively Activated by Designer Drugs).
Team · 3
Fadi Assaf
Founder · CEO & Co-founder
Yitzhak Schiller
Founder · Co-founder
Liora Sklair-Tavron
Senior Consultant
Sectors & technology
Primary sector
Drug Discovery
Technologies
Target customers
Business model
B2B
Tags
parkinsonneuro-stimulationbrain-disorder
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | gracegenetherapy.com |
|---|
Identifiers & details
| Legal name | GRACE GENE THERAPY LTD |
|---|---|
| Founded | 2024 |
| Employees (exact) | 7 |
Radar intelligence
Web history (Wayback)
| Domain | gracegenetherapy.com |
|---|
Certificate / subdomain footprint
| Subdomains | 0 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 517016606 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2024-07-23 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | ואדי אל-חאג' 13 נצרת |